Lutris Pharma is a clinical stage biopharmaceutical company focused on improving anti-cancer therapy effectiveness and quality of life for patients who are being treated with EGFR (Epidermal Growth Factor Receptor) inhibitors or with radiation, where dermal toxicity often leads to a reduction of anti-cancer therapy compliance. The company aims to provide novel topical therapies in order to mitigate these side effects. Lutris Pharma’s lead asset, LUT014, a topical B-Raf Inhibitor, is a proprietary, first-in-class, small molecule currently in a phase 2 clinical trial in metastatic colorectal cancer patients with EGFR inhibitor induced acneiform lesions and a phase 1/2 study for the treatment of radiation-induced dermatitis.
Location: Israel, Tel Aviv District, Tel Aviv-Yafo
Employees: 11-50
Total raised: $35M
Founded date: 2015
Investors 3
| Date | Name | Website |
| 13.07.2025 | aMoon Fund | amoon.fund... |
| - | Arkin Hold... | arkinholdi... |
| - | Pontifax V... | pontifax.c... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 03.02.2025 | - | $30M | - |
| 24.10.2022 | Grant | $5M | - |
Mentions in press and media 5
| Date | Title | Description |
| 04.02.2025 | Lutris Pharma Secures $30 Million to Tackle Cancer Treatment Side Effects | Lutris Pharma, a clinical-stage biopharmaceutical company based in Tel Aviv, has successfully raised $30 million in funding. This financial boost is aimed at advancing the development of LUT014, a topical gel designed to alleviate a common ... |
| 03.02.2025 | Lutris Pharma: $30 Million Funding Raised For Advancing Development Of Anti-Cancer Drug Effectiveness | Lutris Pharma – a clinical-stage biopharmaceutical company focused on improving anti-cancer therapies by reducing cutaneous dose-limiting toxicity – announced that it has secured $30 million in financing to advance the development of LUT014... |
| 28.01.2025 | Lutris Pharma Raises $30M in Funding | Lutris Pharma, a Tel Aviv, Israel-based clinical stage biopharmaceutical company, raised $30M in funding. The round was led by Columbus Venture Partners and Pontifax Venture Capital, with participation from an existing investor, with Peregr... |
| 24.10.2022 | Lutris Pharma's Founder and Chairman of the Board Receives $5.0 Million Grant from the California Institute of Regenerative Medicine (CIRM) to Develop LUT017 for Wound Healing | TEL AVIV, Israel, Oct. 24, 2022 /PRNewswire/ -- Lutris Pharma, a clinical stage biopharmaceutical company focused on improving anti-cancer therapies by reducing dose limiting side effects, today announced that the California Institute of Re... |
| - | Lutris Pharma | “Improving anti-cancer therapy by reducing dose limiting side effects” |